Logo

XAGE

Longevity Health Holdings Inc.

XAGE

Longevity Health Holdings Inc. • NASDAQ
$0.54 ▲ 3.26% (+0.02)
Market Cap $799736
52w High $36.00
52w Low $0.43
Dividend Yield 0%
P/E -0.11
Volume 608
Outstanding Shares 1.48M

Income Statement

Period Revenue Operating Expense Net Income Net Profit Margin Earnings Per Share EBITDA
Q3-2025 $425.864K ▼ $1.678M ▼ $-1.43M ▲ -335.73% ▲ $-0.83 ▼ $-1.502M ▲
Q2-2025 $503.612K ▼ $2.161M ▲ $-1.886M ▼ -374.582% ▼ $-0.09 ▼ $-1.818M ▼
Q1-2025 $510.353K ▲ $1.777M ▲ $-1.506M ▼ -295.064% ▲ $-0.072 ▼ $-1.427M ▼
Q4-2024 $17.479K ▼ $1.023M ▼ $-914.283K ▲ -5.231K% ▲ $-0.044 ▲ $-965.51K ▲
Q3-2024 $20.519K $1.435M $-2.878M -14.028K% $-0.14 $-2.828M

Balance Statement

Period Cash & Short-term Total Assets Total Liabilities Total Equity
Q3-2025 $1.109M ▼ $3.299M ▼ $7.276M ▼ $-3.977M ▼
Q2-2025 $1.551M ▲ $3.719M ▲ $7.457M ▲ $-3.738M ▲
Q1-2025 $770.047K ▲ $3.337M ▲ $7.143M ▲ $-3.805M ▲
Q4-2024 $157.139K ▼ $1.474M ▼ $6.187M ▼ $-4.713M ▼
Q3-2024 $1.137M $2.442M $6.506M $-4.065M

Cash Flow Statement

Period Net Income Cash From Operations Cash From Investing Cash From Financing Net Change Free Cash Flow
Q3-2025 $-1.43M ▲ $-1.434M ▼ $776 ▲ $991.009K ▼ $-441.971K ▼ $-1.448M ▼
Q2-2025 $-1.886M ▼ $-836.19K ▼ $-15K ▲ $1.632M ▲ $781.152K ▲ $-836.19K ▼
Q1-2025 $-1.506M ▼ $-752.953K ▲ $-150K ▼ $1.516M ▲ $612.908K ▲ $-752.953K ▲
Q4-2024 $-814.283K ▲ $-772.063K ▲ $0 $-208.123K ▼ $-980.186K ▲ $-772.063K ▲
Q3-2024 $-1.626M $-1.403M $0 $341.681K $-1.061M $-1.403M

Five-Year Company Overview

Income Statement

Income Statement The company is still essentially pre-revenue, with no meaningful sales reported over the last several years. Operating results show recurring losses, but on a relatively small scale, which is typical for an early-stage biotech focused on development rather than commercialization. Earnings per share look sharply negative mainly because of the tiny equity base and later reverse split, rather than because of large absolute losses. Overall, the income statement tells a story of a business still in the build-out phase, with costs consistently exceeding income and profitability likely some distance away, dependent on successful product rollout and integration of the plasma business.

Balance Sheet

Balance Sheet The balance sheet appears very lean, with only modest reported assets and no visible cash cushion in the summarized data, which signals limited financial flexibility. Equity has swung between negative and slightly positive over time, reflecting a history of accumulated losses offset by periodic capital infusions or restructurings. Debt levels look very low, so the company is not weighed down by leverage, but it also means future growth will likely continue to rely on raising fresh capital or generating cash from new operations. The overall picture is of a small, thinly capitalized platform that needs scale and execution to strengthen its financial foundation.

Cash Flow

Cash Flow Reported cash flows from operations are slightly negative and very small in absolute terms, consistent with a business that has not yet scaled commercial activity. Capital spending is negligible, so free cash flow is driven almost entirely by operating losses rather than heavy investment in physical assets. This pattern suggests the company’s main cash needs are for research, development, and corporate costs, rather than factories or equipment. With limited internal cash generation, the company’s ability to fund growth hinges on access to external funding and on bringing the plasma and product businesses to a point where they can produce steady cash inflows.

Competitive Edge

Competitive Edge Longevity Health Holdings is trying to carve out a distinct niche at the intersection of aesthetics, regenerative medicine, and longevity, which is a fast-growing but crowded space. Its key advantage lies in proprietary human biology–based platforms (Carmell Secretome and Elevai Exosomes) and in securing its own plasma supply chain through the THPlasma merger, which could lower input risk and costs while giving it a secure source of critical raw materials. The planned integration of diagnostics with topical and procedural products, if executed, would differentiate the brand by tying skin and hair outcomes to measurable biology. At the same time, the company faces intense competition from big cosmetic, dermatology, and biotech players, along with regulatory, scientific, and commercialization risks common to early-stage, science-driven platforms.

Innovation and R&D

Innovation and R&D The company’s core strength is its investment in specialized regenerative technologies built around human-derived secretomes and exosomes, which aim to enhance healing, skin rejuvenation, and hair growth by working with the body’s own signaling systems. Years of research and significant spending have gone into creating stable, potent formulations and into a proprietary exosome platform that emphasizes safety, purity, and consistency. Its “Built by Biology” and “clean formulation” approach, including avoidance of a group of controversial cosmetic additives, aligns with consumer and practitioner interest in more natural yet science-backed products. Upcoming launches in hair growth and advanced skincare, plus a long-term ambition to link products to biomarker-based diagnostics, show a strong innovation pipeline, but the real test will be clinical validation, regulatory clarity, and market adoption at scale.

Summary

Overall, Longevity Health Holdings looks like a science-first, pre-revenue bio-aesthetics platform trying to transition into a commercially meaningful, vertically integrated longevity company. Financially, it is still very early-stage, with minimal assets, ongoing losses, and dependence on external capital rather than internally generated cash. Strategically, its combination of proprietary biological technologies, control over plasma sourcing, and a broad “healthy aging inside and out” vision offers clear potential but comes with high execution and market risks. Key things to watch include how well the THPlasma business is integrated, whether new product launches gain real traction with practitioners and consumers, and how quickly the company can move from an R&D story to one with durable, diversified revenue streams.